Skip to content

Nutritional Counseling and Oral Nutritional Supplements (ONS) in Head and Neck Cancer Patients Undergoing Radiotherapy

Nutritional Counseling and Oral Nutritional Supplements (ONS) in Head and Neck Cancer Patients Undergoing Radiotherapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200057806
Enrollment
Unknown
Registered
2022-03-17
Start date
2022-03-04
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Head and Neck Cancers

Interventions

Experimental group:Nutritional Counseling plus Oral Nutritional Supplements (ONS)
Control group:Nutritional Counseling

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years old; 2. Newly diagnosed HNC and planned to undergo radiotherapy or newly diagnosed HNC with previous surgical treatment history and planned to undergo radiotherapy; 3. KPS score >= 70 or ECOG score =4*10^9/L, ANC>=1.5*10^9/L, HGB>=9g/L, PLT>=100*10^9/L; 9. Blood biochemical outcomes: normal liver function (or TBIL, AST, ALT = ml/min or CRE <=1.5 times the upper limit of normal value).

Exclusion criteria

Exclusion criteria: 1. Has other malignancy; 2. Severe digestive system diseases; 3. Severe heart, lung, liver and kidney function insufficiency; 4. Currently undergoing other forms of nutritional treatment; 5. Refuse to use ONS; 6. Vulnerable groups, including mental illness patients, cognitively impaired patients, critically ill patients, minors, pregnant women, and etc.

Design outcomes

Primary

MeasureTime frame
Body Weight Change;Body Mass Index;

Secondary

MeasureTime frame
Toxicity Criteria of the Radiation Therapy Oncology Group;Quality of Life Score;PG-SGA (Patient-generated subjective nutrition assessment) Score;Handgrip Strength;Skinfold Thickness;Fat Free Mass Index;L3-CT Skeletal Muscle Index;Plasma Protein Levels;T Lymphocyte Subpopulations Analysis ;Adverse Effects/Events;Response Rate;1 or 2 Years Survival Rate;Progression-free survival;Overall Survival;

Countries

China

Contacts

Public ContactSun Xiaonan

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

srrshgs@163.com+86 0571-86006667

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026